FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a method for obtaining purified single-stranded RNA (hereinafter – ssRNA) (options). In one implementation, the method includes stages of (i) producing RNA preparation containing ssRNA using in vitro transcription, (ii) bringing RNA preparation into contact with cellulose material under conditions that provide for the possibility of binding double-stranded RNA (hereinafter – dsRNA) with cellulose material and do not allow ssRNA to bind with cellulose material; and (iii) separating ssRNA from cellulose material under conditions that provide for the possibility of binding dsRNA with cellulose material and do not allow ssRNA to bind with cellulose material.
EFFECT: invention expands the arsenal of methods for preparing purified single-stranded RNA.
39 cl, 11 dwg, 11 ex
Title | Year | Author | Number |
---|---|---|---|
mRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | 2020 |
|
RU2810003C2 |
METHODS AND COMPOSITIONS FOR TREATMENT OF BLEEDING PHENOMENON IN HEMOPHILIA PATIENTS | 2018 |
|
RU2801263C2 |
METHODS FOR PURIFYING MATRIX RNA | 2020 |
|
RU2825579C2 |
FORMULA FOR INTRODUCING RNA | 2019 |
|
RU2797147C2 |
NEW IMMUNOGENIC EXTRACT OF FUNGI AND PATTERN-RECOGNITION RECEPTOR OF PLANTS | 2013 |
|
RU2700621C2 |
STABLE COMPOSITIONS OF LIPIDS AND LIPOSOMES | 2015 |
|
RU2738060C2 |
TREATMENT DISEASES, ASSOCIATED WITH INTERFERON-REGULATORY FACTOR 8 (IRF8), BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRF8 | 2011 |
|
RU2611187C2 |
TREATMENT OF RNase H1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNase H1 | 2011 |
|
RU2611192C2 |
TREATMENT OF FIBROBLAST GROWTH FACTOR 21 (FGF21) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO FGF21 | 2011 |
|
RU2610661C2 |
RNA FOR TREATMENT OF AUTOIMMUNE DISEASES | 2018 |
|
RU2790447C2 |
Authors
Dates
2021-11-30—Published
2017-04-19—Filed